Safinamide as an Adjunct Therapy for Motor Symptoms and ON-Time Extension in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Objective: To evaluate the efficacy of safinamide as an adjunct therapy in improving motor symptoms and extending ON-time in patients with Parkinson’s disease (PD). Background:…A matching-adjusted indirect comparison of efficacy and safety for safinamide versus rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson’s disease
Objective: To compare efficacy and safety of safinamide and rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson’s disease (PD) by matching-adjusted indirect…The monoamine oxidase-B inhibitor selegiline does not affect 18F-Florzolotau uptake in patients with progressive supranuclear palsy: a longitudinal case series
Objective: In a longitudinal case series of patients with progressive supranuclear palsy (PSP), a chronic challenge with the irreversible MAO-B inhibitor selegiline was used to…Estrogen and progesterone influence membrane functions and glucose transporter expression in synaptosomes of different age groups of naturally menopausal rats
Objective: The objective of this study was to determine the effect of 17 β-estradiol (E2) and progesterone (P4) on the activities of Na+ K+ ATPase, monoamine…Selegiline drives autophagic secretion of α-synuclein
Objective: Our aim is to elucidate how selegiline drives extracellular secretion of α-synuclein (αS) and whether selegiline-induced αS secretion affects cell-to-cell transmission of αS. Background:…Dyskinesia and adherence to safinamide and opicapone in fluctuating patients with Parkinson’s disease: observational retrospective study
Objective: To assess differences in the new onset or worsening of baseline dyskinesia after the introduction of safinamide (SA) or opicapone (OP) as add-on therapy…Dopamine dysregulation syndrome in Parkinson’s disease controlled by safinamine
Objective: To describe a case of dopamine dysregulation syndrome managed by safinamide. Background: Dopamine dysregulation syndrome (DDS) is an uncommon non-motor symptom of Parkinson disease…SAFE-DBS – A monocentric, randomised, blind evaluation of safinamide in the perioperative period in Parkinsonian patients with deep brain stimulation
Objective: This monocentric, randomised, blind study is designed to evaluate the effect of safinamide on motor and neuropsychiatric symptoms in the 3 month perioperative period…The efficacy of dopamine agonists or monoamine oxidase type B inhibitors as monotherapy in patients with early Parkinson disease: A network meta-analysis
Objective: This study aimed to investigate the effectiveness of dopamine agonists or monoamine oxidase type B inhibitors (MAOB-I) as monotherapy in patients with early Parkinson's…Collective expert perspectives on the use of safinamide as adjunctive therapy for Parkinson’s disease in Japan: Online-based Delphi approach
Objective: To summarize opinions on the optimal patient profile and methods of using safinamide in common clinical scenarios, Japanese movement disorder specialists with expertise in…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 7
- Next Page »